Literature DB >> 8226431

Bactericidal activity of two different dosage regimens of imipenem in an in-vitro dynamic model.

F Maggiolo1, A Taras, S Frontespezi, F Bottari, M C Legnani, F Suter.   

Abstract

The antimicrobial activity of imipenem was tested in an in-vitro model mimicking human serum pharmacokinetics after either 1000 mg im once daily or 500 mg im twice daily. Six recent clinical isolates of Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae and Salmonella group B were used as test strains. Our results suggest that a single daily dose of imipenem 1000 mg im exerts an antibacterial action comparable to that obtained with two divided doses of 500 mg.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8226431     DOI: 10.1093/jac/32.2.295

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions.

Authors:  A A Firsov; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

3.  Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models.

Authors:  S Keil; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

4.  Pharmacodynamic effects of subinhibitory concentrations of imipenem on Pseudomonas aeruginosa in an in vitro dynamic model.

Authors:  F Maggiolo; A Taras; S Frontespezi; M C Legnani; M A Silanos; G Pravettoni; F Suter
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 5.  Continuous infusion of beta-lactam antibiotics.

Authors:  A P MacGowan; K E Bowker
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

6.  Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.

Authors:  Alasdair P MacGowan; Karen E Bowker; Alan R Noel
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

7.  A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.

Authors:  Nageshwar R Budha; Robin B Lee; Julian G Hurdle; Richard E Lee; Bernd Meibohm
Journal:  Tuberculosis (Edinb)       Date:  2009-09-11       Impact factor: 3.131

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.